Exfoliative esophagitis secondary to tislelizumab: a case report
Tislelizumab, as a PD-1 inhibitor, has demonstrated significant efficacy in cancer treatment. However, it may also induce immune-related adverse events (irAEs). This case report describes a patient who developed oral ulcers and dysphagia following treatment with tislelizumab, which was diagnosed as...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1498253/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846149953121943552 |
|---|---|
| author | Mingxing Wang Qingming Sun Wanhui Dong |
| author_facet | Mingxing Wang Qingming Sun Wanhui Dong |
| author_sort | Mingxing Wang |
| collection | DOAJ |
| description | Tislelizumab, as a PD-1 inhibitor, has demonstrated significant efficacy in cancer treatment. However, it may also induce immune-related adverse events (irAEs). This case report describes a patient who developed oral ulcers and dysphagia following treatment with tislelizumab, which was diagnosed as exfoliative esophagitis through endoscopic examination. The condition improved after corticosteroid pulse therapy. A review of the relevant literature revealed no prior reports of immune checkpoint inhibitor (ICI)-related esophagitis cases, prompting an exploration of the potential pathophysiological mechanisms and therapeutic strategies. This report emphasizes the importance of vigilance for rare irAEs during ICI therapy, advocating for early detection and timely intervention. |
| format | Article |
| id | doaj-art-57dbe5b0a4c348108d912d654679460e |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-57dbe5b0a4c348108d912d654679460e2024-11-29T08:57:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14982531498253Exfoliative esophagitis secondary to tislelizumab: a case reportMingxing WangQingming SunWanhui DongTislelizumab, as a PD-1 inhibitor, has demonstrated significant efficacy in cancer treatment. However, it may also induce immune-related adverse events (irAEs). This case report describes a patient who developed oral ulcers and dysphagia following treatment with tislelizumab, which was diagnosed as exfoliative esophagitis through endoscopic examination. The condition improved after corticosteroid pulse therapy. A review of the relevant literature revealed no prior reports of immune checkpoint inhibitor (ICI)-related esophagitis cases, prompting an exploration of the potential pathophysiological mechanisms and therapeutic strategies. This report emphasizes the importance of vigilance for rare irAEs during ICI therapy, advocating for early detection and timely intervention.https://www.frontiersin.org/articles/10.3389/fonc.2024.1498253/fulltislelizumabexfoliative esophagitisimmune checkpoint inhibitorsimmune-related adverse eventscase report |
| spellingShingle | Mingxing Wang Qingming Sun Wanhui Dong Exfoliative esophagitis secondary to tislelizumab: a case report Frontiers in Oncology tislelizumab exfoliative esophagitis immune checkpoint inhibitors immune-related adverse events case report |
| title | Exfoliative esophagitis secondary to tislelizumab: a case report |
| title_full | Exfoliative esophagitis secondary to tislelizumab: a case report |
| title_fullStr | Exfoliative esophagitis secondary to tislelizumab: a case report |
| title_full_unstemmed | Exfoliative esophagitis secondary to tislelizumab: a case report |
| title_short | Exfoliative esophagitis secondary to tislelizumab: a case report |
| title_sort | exfoliative esophagitis secondary to tislelizumab a case report |
| topic | tislelizumab exfoliative esophagitis immune checkpoint inhibitors immune-related adverse events case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1498253/full |
| work_keys_str_mv | AT mingxingwang exfoliativeesophagitissecondarytotislelizumabacasereport AT qingmingsun exfoliativeesophagitissecondarytotislelizumabacasereport AT wanhuidong exfoliativeesophagitissecondarytotislelizumabacasereport |